Amgen Inc. (AMGN)
NASDAQ: AMGN
· Real-Time Price · USD
288.09
4.55 (1.60%)
At close: May 30, 2025, 3:59 PM
287.45
-0.22%
After-hours: May 30, 2025, 05:55 PM EDT
Amgen Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aranesp Revenue | 1.34B | 1.36B | 1.52B | 1.68B | 1.18B | 1.73B | 1.88B | 2.05B | 2.09B | 1.95B | 1.93B | 1.91B | 2.04B |
| Aranesp Revenue Growth | -1.47% | -10.51% | -9.51% | +42.06% | -31.52% | -7.88% | -8.57% | -1.91% | +7.28% | +1.09% | +0.99% | -6.32% | n/a |
| BLINCYTO Revenue | 1.22B | 861M | 1.42B | 1.48B | 1.57B | 5.23B | 5.01B | 175M | 115M | 5.36B | 3M | 4.55B | 4.24B |
| BLINCYTO Revenue Growth | +41.23% | -39.41% | -3.99% | -5.61% | -70.00% | +4.23% | +2765.14% | +52.17% | -97.86% | +178700.00% | -99.93% | +7.44% | n/a |
| ENBREL Revenue | 3.32B | 3.7B | 4.12B | 4.46B | 5B | 1.04B | 4.31B | 5.43B | 5.96B | 512M | 4.69B | 73M | 368M |
| ENBREL Revenue Growth | -10.31% | -10.20% | -7.79% | -10.63% | +378.54% | -75.75% | -20.74% | -8.92% | +1065.04% | -89.08% | +6321.92% | -80.16% | n/a |
| EVENITY Revenue | 1.56B | 272M | 1.25B | 1.11B | 1.06B | 4.96B | 2.29B | 835M | 692M | 525M | 331M | 427M | 472M |
| EVENITY Revenue Growth | +474.63% | -78.19% | +12.55% | +4.04% | -78.52% | +116.46% | +174.37% | +20.66% | +31.81% | +58.61% | -22.48% | -9.53% | n/a |
| KRYSTEXXA Revenue | 1.19B | 1.4B | 1.31B | 1.03B | 2.19B | 1.16B | 1.79B | 642M | 584M | 1.31B | 469M | 744M | 359M |
| KRYSTEXXA Revenue Growth | -15.54% | +7.35% | +27.26% | -53.21% | +89.55% | -35.16% | +178.19% | +9.93% | -55.49% | +179.74% | -36.96% | +107.24% | n/a |
| Kyprolis Revenue | 1.5B | 1.48B | 2.29B | 2.25B | 6.57B | 2.67B | 1.21B | 1.97B | 1.64B | 549M | 1.03B | 389M | 748M |
| Kyprolis Revenue Growth | +1.76% | -35.45% | +1.73% | -65.79% | +146.03% | +120.10% | -38.31% | +20.37% | +197.81% | -46.70% | +164.78% | -47.99% | n/a |
| Nplate Revenue | 1.46B | 2.19B | 5.57B | 5.85B | 2.76B | 1.94B | n/a | 642M | 611M | 1.41B | 505M | 1.02B | n/a |
| Nplate Revenue Growth | -33.46% | -60.72% | -4.80% | +111.76% | +42.79% | n/a | n/a | +5.07% | -56.51% | +178.22% | -50.44% | n/a | n/a |
| Otezla Revenue | 2.13B | 5.26B | 3.63B | 3.25B | 887M | n/a | n/a | 1.57B | 1.53B | n/a | 1.22B | n/a | n/a |
| Otezla Revenue Growth | -59.60% | +45.07% | +11.70% | +266.18% | n/a | n/a | n/a | +3.01% | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue | 5.63B | 1.28B | 1.3B | 1.12B | 1.9B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products Revenue Growth | +339.84% | -1.23% | +16.03% | -41.18% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product and Service, Other Revenue | 1.4B | 4.05B | 2.01B | 2.02B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product and Service, Other Revenue Growth | -65.46% | +100.99% | -0.20% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Prolia Revenue | 4.37B | 1.64B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Prolia Revenue Growth | +167.52% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Repatha (evolocumab) Revenue | 2.22B | 448M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Repatha (evolocumab) Revenue Growth | +395.98% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEPEZZA Revenue | 1.85B | 984M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEPEZZA Revenue Growth | +88.11% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEZSPIRE Revenue | 972M | 2.11B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEZSPIRE Revenue Growth | -53.98% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vectibix Revenue | 1.04B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vectibix Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| XGEVA Revenue | 2.23B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| XGEVA Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 9.56B | 8.38B | 7.73B | 7.79B | 6.93B | 6.14B | 5.39B | 4.82B | 4.67B | 4.5B | 4.67B | 4.2B | 1.32B |
| Non-Us Revenue Growth | +14.04% | +8.49% | -0.73% | +12.37% | +12.87% | +13.90% | +11.80% | +3.32% | +3.78% | -3.69% | +11.22% | +218.60% | n/a |
| United States Revenue | 23.86B | 19.81B | 18.59B | 18.19B | 18.5B | 17.22B | 18.36B | 18.03B | 18.33B | 17.17B | 15.4B | 14.48B | 3.7B |
| United States Revenue Growth | +20.48% | +6.51% | +2.20% | -1.63% | +7.39% | -6.18% | +1.82% | -1.62% | +6.75% | +11.50% | +6.33% | +291.25% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.69B | 1.88B | 1.63B | 1.78B | 1.81B | 2.27B | 1.35B | 1.29B | 1.26B | 1.57B | 1.29B | 1.33B | 1.23B | 1.43B | 1.3B | 1.38B | 1.25B | 1.77B | 1.35B | 1.29B | 1.32B | 1.51B | 1.22B | 1.26B | 1.15B | 1.56B | 1.29B | 1.35B | 1.13B | 1.43B | 1.17B | 1.21B | 1.06B | 1.32B | 1.24B | 1.29B | 1.2B | 1.42B | 1.24B | 1.16B | 1.03B |
| Selling, General, and Administrative Revenue Growth | -10.17% | +15.57% | -8.96% | -1.27% | -20.49% | +68.07% | +4.56% | +2.86% | -19.97% | +22.14% | -3.01% | +8.06% | -13.82% | +9.20% | -5.71% | +10.37% | -29.27% | +31.72% | +3.94% | -1.60% | -13.02% | +23.71% | -2.94% | +9.19% | -25.98% | +20.57% | -4.43% | +20.05% | -21.02% | +21.97% | -3.23% | +13.63% | -19.58% | +6.35% | -3.72% | +7.40% | -15.04% | +13.83% | +7.24% | +13.06% | n/a |
| Research and Development Revenue | 1.49B | 1.72B | 1.45B | 1.45B | 1.34B | 1.53B | 1.08B | 1.11B | 1.06B | 1.32B | 1.11B | 1.04B | 959M | 1.35B | 1.42B | 1.08B | 967M | 1.23B | 1.06B | 964M | 952M | 1.31B | 1B | 924M | 879M | 1.18B | 926M | 869M | 760M | 1.04B | 877M | 873M | 769M | 1.08B | 990M | 900M | 872M | 1.09B | 1.12B | 964M | 894M |
| Research and Development Revenue Growth | -13.81% | +18.90% | +0.21% | +7.74% | -12.45% | +42.17% | -3.05% | +5.20% | -20.09% | +19.06% | +7.03% | +8.34% | -28.86% | -5.20% | +31.42% | +11.89% | -21.32% | +15.73% | +10.17% | +1.26% | -27.44% | +31.07% | +8.33% | +5.12% | -25.63% | +27.65% | +6.56% | +14.34% | -27.13% | +18.93% | +0.46% | +13.52% | -28.66% | +8.89% | +10.00% | +3.21% | -20.22% | -2.32% | +16.08% | +7.83% | n/a |